Clinical Trial Update: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS [Phase 1]

View source ↗

Summary

A Phase 1 study from Novartis evaluating PDR001 and MBG453 with decitabine in acute myeloid leukemia or high-risk myelodysplastic syndromes has completed; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• MBG453
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukemia, Leukemia, Myeloid | Phase 1 | Status: COMPLETED